ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near ...

Sleep apnea affects over 29 million Americans, with Obstructive Sleep Apnea (characterized by pauses in breathing during ...

Turkey: A recent study published in The Laryngoscope revealed a significant relationship between laryngopharyngeal reflux ...

The ResMed share price is having a tough start to the week. Is this a buying opportunity for investors? Let's find ...

While Continuous Positive Airway Pressure (CPAP) machines have long been the standard treatment, many patients find them uncomfortable or difficult to use. Fortunately, Sleep Solution Centers, a ...

For years, Michelle Strickland had trouble sleeping – she woke up several times at night – and it left her with daytime sleepiness and her body craving lots of naps. Strickland recently went ...

Vitamin D deficiency has been linked to poor sleep quality and duration, affecting roughly 35% of Americans. Research ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

Shares of ResMed (NYSE:RMD) fell 6% today, despite the company reporting second-quarter earnings that surpassed analyst ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...